Epigenetic treatment‑mediated modulation of PD‑L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD‑L1 reverse signaling

Liu,Hongbin; Hu,Yunshan; Rimoldi,Rafael; Von Hagt,Chloe; Khong,Edmund  W.C.; Lee,Nora; Flemming,Shaun; Spencer,Andrew; Dear,Anthony  E.

doi:10.3892/ol.2018.9841

Epigenetic treatment‑mediated modulation of PD‑L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD‑L1 reverse signaling

Authors:
- Hongbin Liu
- Yunshan Hu
- Rafael Rimoldi
- Chloe Von Hagt
- Edmund W.C. Khong
- Nora Lee
- Shaun Flemming
- Andrew Spencer
- Anthony E. Dear
View Affiliations

Affiliations: Department of Medicine, Eastern Health Clinical School, Monash University, Melbourne, Victoria 3128, Australia, Department of Haematology, Eastern Health Clinical School, Box Hill Hospital, Melbourne, Victoria 3128, Australia, Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria 3004, Australia
Published online on: December 17, 2018 https://doi.org/10.3892/ol.2018.9841
Pages: 2543-2550

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent evidence suggests an association exists between resistance to epigenetic therapy (EGT) and the expression of programmed cell death protein 1 (PD‑1) and programmed death‑ligand 1 (PD‑L1) in myeloid malignancies. Biomarkers are required to predict resistance to EGT in myeloid malignancies, which together with the delineation of associated molecular mechanisms, may provide additional understanding for novel treatment strategies when investigating resistance to EGT. The present study aimed to investigate the in vivo effects of EGT on the expression of PD‑1, PD‑L1 and orphan nuclear receptor NUR77 with clinical responses in patients with myeloid malignancies. In addition, in vitro and in vivo characterization of the effects of EGT on the expression of NF‑κB and Bcl‑xL, potential downstream targets of PD‑L1 reverse signaling, were evaluated to determine components of the molecular mechanism responsible for these effects. The in vivo effects of EGT on the expression of PD‑1, PD‑L1 and a previously identified molecular marker of response to EGT, NUR77 was characterized in peripheral blood mononuclear cells (PBMC) from patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treated with either azacytidine (Aza) alone or a combination of Aza and the histone deacetylase inhibitor (HDACi) LBH‑589 during the first cycle of therapy. The correlation of clinical responses to treatment with EGT with the expression of PD‑1, PD‑L1 and NUR77 demonstrated that the induction of PD‑L1 mRNA levels was associated with resistance to EGT despite the concurrent augmentation of NUR77 expression. The characterization of potential downstream effector molecules of reverse PD‑L1 signaling identified EGT‑mediated induction of Bcl‑xL and NF‑κB mRNA expression in vitro and in vivo, suggesting a potential anti‑apoptotic molecular mechanism was responsible for PD‑L1‑mediated resistance to EGT. Taken together, these observations suggest that enhanced PD‑L1 expression may confer resistance to EGT over known EGT response markers in myeloid malignancies, and provides a potential molecular mechanism involving the modulation of effectors of PD‑L1 reverse signaling, which may in‑part, be responsible for these effects.

View Figures

View References

1	Yun S, Vincelette ND, Abraham I, Robertson KD, Fernandez-Zapico ME and Patnaik MM: Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: A systematic review of hypomethylating agents trials. Clin Epigenetics. 8:682016. View Article : Google Scholar : PubMed/NCBI
2	Unnikrishnan A, Papaemmanuil E, Beck D, Deshpande NP, Verma A, Kumari A, Woll PS, Richards LA, Knezevic K, Chandrakanthan V, et al: Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes. Cell Rep. 20:572–585. 2017. View Article : Google Scholar : PubMed/NCBI
3	Cheng JX, Chen L, Li Y, Cloe A, Yue M, Wei J, Watanabe KA, Shammo JM, Anastasi J, Shen QJ, et al: RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat Commun. 9:11632018. View Article : Google Scholar : PubMed/NCBI
4	Vidal V, Robert G, Goursaud L, Durand L, Ginet C, Karsenti JM, Luciano F, Gastaud L, Garnier G, Braun T, et al: BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia. Oncotarget. 8:47103–47109. 2017. View Article : Google Scholar : PubMed/NCBI
5	Miltiades P, Lamprianidou E, Vassilakopoulos TP, Papageorgiou SG, Galanopoulos AG, Kontos CK, Adamopoulos PG, Nakou E, Vakalopoulou S, Garypidou V, et al: The Stat3/5 signaling biosignature in hematopoietic stem/progenitor cells predicts response and outcome in myelodysplastic syndrome patients treated with azacitidine. Clin Cancer Res. 22:1958–1968. 2016. View Article : Google Scholar : PubMed/NCBI
6	Daver N, Boddu P, Garcia-Manero G, Yadav SS, Sharma P, Allison J and Kantarjian H: Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 32:1094–1105. 2018. View Article : Google Scholar : PubMed/NCBI
7	Wolff F, Leisch M, Greil R, Risch A and Pleyer L: The double-edged sword of (re)expression of genes by hypomethylating agents: From viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation. Cell Commun Signal. 15:132017. View Article : Google Scholar : PubMed/NCBI
8	Granier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E, Saldmann A, Gey A, Oudard S and Tartour E: Mechanisms of action and rational for the use of checkpoint inhibitors in cancer. ESMO Open. 2:e0002132017. View Article : Google Scholar : PubMed/NCBI
9	Liu HB, Urbanavicius D, Tan P, Spencer A and Dear AE: Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies. Int J Oncol. 45:1742–1748. 2014. View Article : Google Scholar : PubMed/NCBI
10	Lübbert M, Ihorst G, Sander PN, Bogatyreva L, Becker H, Wijermans PW, Suciu S, Bissé E and Claus R: Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2′-deoxycytidine (Decitabine). Br J Haematol. 176:609–617. 2017. View Article : Google Scholar : PubMed/NCBI
11	Zhou L, Ruvolo VR, McQueen T, Chen W, Samudio IJ, Conneely O, Konopleva M and Andreeff M: HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML. Leukemia. 27:1358–1368. 2013. View Article : Google Scholar : PubMed/NCBI
12	Dear AE, Liu HB, Mayes PA and Perlmutter P: Conformational analogues of oxamflatin as histone deacetylase inhibitors. Org Biomol Chem. 4:3778–3784. 2006. View Article : Google Scholar : PubMed/NCBI
13	Tan P, Wei A, Mithraprabhu S, Cummings N, Liu HB, Perugini M, Reed K, Avery S, Patil S, Walker P, et al: Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer J. 4:e1702014. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, et al: Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 108:419–425. 2006. View Article : Google Scholar : PubMed/NCBI
16	Dail M, Yang L, Green C, Ma C, Robert A, Kadel EE, Koeppen H, Adamkewicz J, Byon J, Woodard J, et al: Distinct patterns of PD-L1 and PD-L2 expression by tumor and non-tumor cells in patients with MM, MDS and AML. Blood. 128:13402016.
17	Coats T, Smith AE, Mourikis TP, Irish JM, Kordasti S and Mufti GJ: Mass cytometry reveals PD1 upregulation is an early step in MDS disease progression. Blood. 128:42962016.
18	Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng QR, Fang Z, Nguyen M, Pierce S, Wei Y, et al: Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 28:1280–1288. 2014. View Article : Google Scholar : PubMed/NCBI
19	Azuma T, Yao S, Zhu G, Flies AS, Flies SJ and Chen L: B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood. 111:3635–3643. 2008. View Article : Google Scholar : PubMed/NCBI
20	Ball B, Zeidan A, Gore SD and Prebet T: Hypomethylating agent combination strategies in myelodysplastic syndromes: Hopes and shortcomings. Leuk Lymphoma. 58:1022–1036. 2017. View Article : Google Scholar : PubMed/NCBI
21	Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, Drerup JM, Padron A, Conejo-Garcia J, Murthy K, et al: Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res. 76:6964–6974. 2016. View Article : Google Scholar : PubMed/NCBI
22	Lainey E, Wolfromm A, Marie N, Enot D, Scoazec M, Bouteloup C, Leroy C, Micol JB, De Botton S, Galluzzi L, et al: Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia. Oncogene. 32:4331–4342. 2013. View Article : Google Scholar : PubMed/NCBI
23	Maiso P, Colado E, Enrique MO, Garayoa M, Atadja P, Pandiella A and San Miguel JF: Panobinostat (LBH589) a promising new partner for combination with doxorubicin in acute myeloid leukemia. Blood. 112:16382008.PubMed/NCBI
24	Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, et al: Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell. 162:974–986. 2015. View Article : Google Scholar : PubMed/NCBI
25	Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, Han H, Liang G, Jones PA, Pugh TJ, et al: DNA-Demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell. 162:961–973. 2015. View Article : Google Scholar : PubMed/NCBI
26	Dear AE: Epigenetic modulators and the new immunotherapies. N Engl J Med. 374:684–686. 2016. View Article : Google Scholar : PubMed/NCBI